Drug Profile
Guanfacine once-daily - Takeda
Alternative Names: Guanfacine Carrier Wave; SPD 547Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Shire
- Class Acetamides; Centrally-acting antihypertensives; Chlorobenzenes; Guanidines; Phenylacetates; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Attention-deficit hyperactivity disorder; Autistic disorder
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 28 Jul 2018 No recent reports of development identified for phase-I development in Anxiety-disorders(In children) in Unknown
- 28 Jul 2018 No recent reports of development identified for phase-I development in Attention-deficit-hyperactivity-disorder in Unknown